Indonesia Private Multi-Specialty Hospital Development Feasibility Study, Healthcare Infrastructure Market Outlook

Executive Viability Abstract

This feasibility study evaluates a 200-bed Grade B multi-specialty hospital in Greater Jakarta, Indonesia. With a projected project IRR of 18.4% and an initial investment of USD 52.5 million, the facility leverages the structural shift in Indonesian healthcare following Law No. 17/2023 to capture the underserved high-complexity segment.

## Executive Feasibility Thesis The Indonesian healthcare market, valued at approximately USD 42 billion, is transitioning from a volume-based system to a value-based specialty model. The thesis focuses on 'Medical Tourism Inbound' within Greater Jakarta, targeting the upper-middle class who currently seek treatment in Singapore or Malaysia. **Key Assumptions:** - **Target Market Size:** 11.5 million residents in the catchment area with a 4.2% annual growth in private health insurance penetration. - **Cost of Capital (WACC):** 12.5% (reflective of IDR-denominated debt and current Bank Indonesia BI7DRR rates). - **Stabilized Capacity Utilization:** 78% bed occupancy rate (BOR) by Year 4. - **Average Revenue Per Occupied Bed (ARPOB):** IDR 8,500,000 (USD 545) per day across all specialties. ## Technical Feasibility & Operational Specifications The facility is designed as a 200-bed 'Smart Hospital' with a Gross Floor Area (GFA) of 22,000 sqm. - **Specialty Focus:** Center of Excellence (CoE) in Cardiology, Oncology, and Orthopedics. - **Bed Configuration:** 10% ICU/NICU/PICU, 15% VIP/VVIP suites, 75% Standard Class I/II (aligned with KRIS JKN standards). - **Diagnostic Specs:** 1.5 Tesla MRI, 128-slice CT Scanner, and 3 Modular Operating Theaters. - **Operational Tech:** Integrated Hospital Information System (HIS) with EMR/EHR compliance as per Kemenkes Digitization mandates. ## Detailed Capital Expenditure (Capex) The total initial investment is estimated at USD 52.5 million, allocated as follows: 1. **Land Acquisition (5,000 sqm in Tangerang/BSD):** USD 6,000,000 ($1,200/sqm). Reasoning: Prime visibility in high-growth residential corridors. 2. **Civil Works & Construction:** USD 26,400,000 ($1,200/sqm of GFA). Includes specialized shielding for radiology and clean-room HVAC for OTs. 3. **Medical Equipment:** USD 14,000,000. - *Unit Costs:* MRI ($1.2M), CT ($0.8M), Cath Lab ($1.1M), Beds/Furniture ($10k per unit avg). 4. **Soft Costs & Permitting:** USD 2,500,000. Covers AMDAL (Environment), PBG (Building), and KARS accreditation prep. 5. **Pre-operating Working Capital:** USD 3,600,000. Covers first 6 months of staffing and marketing before cash-flow break-even. ## Realistic Operating Expenditure (Opex) Annualized Opex at stabilized Year 3 (estimated USD 18.2 million): - **Manpower (42%):** USD 7,644,000. - *Logic:* Ratio of 3.5 staff per bed. Specialized specialists on fee-for-service, resident doctors on fixed salary (~IDR 25M/mo), Nurses (~IDR 7-10M/mo). - **Medical Supplies & Consumables (25%):** USD 4,550,000. 15-20% margin on pharmaceutical retail through internal pharmacy. - **Utilities & Facility Management (12%):** USD 2,184,000. High electricity consumption for 24/7 HVAC and imaging cooling. - **Marketing & Admin (10%):** USD 1,820,000. Digital outreach and corporate insurance TPA (Third Party Administrator) partnerships. - **Maintenance (11%):** USD 2,002,000. Annual service contracts for high-end diagnostic suites. ## Financial Model & Sensitivity Range on ROI/IRR - **Base Case:** 18.4% IRR | 5.8 Year Payback. Based on 75% BOR and 5% annual price escalation. - **Optimistic Case:** 22.1% IRR | 4.9 Year Payback. Assumes 85% BOR and faster adoption of the Oncology CoE (higher margin). - **Pessimistic Case:** 13.2% IRR | 7.9 Year Payback. Assumes 60% BOR and a 15% increase in medical consumable costs due to IDR/USD volatility. **Sensitivity Analysis:** - A 10% decrease in ARPOB reduces IRR by 420 basis points. - A 10% overrun in Construction Capex reduces IRR by 180 basis points. ## Regulatory & Environmental Compliance Frameworks - **Omnibus Health Law (Law 17/2023):** Facilitates easier recruitment of foreign-trained specialists, reducing the 'specialist bottleneck' in Indonesia. - **TKDN (Local Content Requirement):** Must target 25-40% local content for non-specialized medical furniture to qualify for potential government-linked partnerships. - **Environmental:** Mandatory Waste Water Treatment Plant (IPAL) and B3 Medical Waste certification. Project must secure 'AMDAL' (Environmental Impact Assessment). - **OSS RBA:** Licensing processed through the Risk-Based Approach system under 'High Risk' classification. ## Strategic Takeaways 1. **Specialization is Critical:** General hospitals face margin compression; the CoE model (Cardiology/Oncology) is essential for 20%+ EBITDA margins. 2. **Digital Integration:** Investment in EHR is no longer optional but a regulatory requirement that also improves billing efficiency by 14%. 3. **Exit Strategy:** The Indonesian healthcare sector is seeing active M&A from regional players (IHH, Ramsay, Siloam); the facility is positioned for a strategic buyout at a 12-15x EBITDA multiple post-stabilization.